Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTate & Lyle Regulatory News (TATE)

Share Price Information for Tate & Lyle (TATE)

Share Price is delayed by 15 minutes
Get Live Data
505.00    4.50 (0.90%)
Bid:
505.00
Ask:
505.50
Spread: 0.50 (0.099%)
Market Cap: £2.23b
TATE Live PriceLast checked at - London Stock Exchange

Intraday Tate & Lyle Share Chart

Directorate Change

27 Mar 2025 07:00

RNS Number : 3843C
Tate & Lyle PLC
27 March 2025
 

27 March 2025

 

 

Tate & Lyle PLC

 

 

BOARD CHANGES

 

Tate & Lyle PLC (the "Company") is pleased to announce that Steve Foots will join the Board as a non-executive director and as a member of the Remuneration and Nominations Committees from the conclusion of the Annual General Meeting which is to be held on 24 July 2025 (the "AGM"), subject to his election at the AGM.

 

Steve is Chief Executive of Croda International Plc, the FTSE100 speciality ingredients business that uses smart science to create high-performance ingredients and solutions that improve lives, a position he has held since 2012. He joined Croda as a graduate trainee in 1990 and during his career with the company has held a number of senior management positions including President of Croda Europe from 2010.  He also serves as the co-Chair of the Chemistry Council, the joint Government / industry sector council for the chemical industry in the UK.

 

The Company also announces that Lars Frederiksen, an independent non-executive director, will retire from the Board from the conclusion of the AGM after serving for a full nine-year term. Lars has served on the Board since April 2016 and was a member of the Remuneration and Nominations Committees.

 

David Hearn, Chair of Tate & Lyle, said: "I am delighted that Steve has agreed to join the Board. His strategic and operational leadership experience, and deep understanding of the importance of customer focus and innovation, will be of significant benefit to the Board as we deliver on Tate & Lyle's growth agenda. I am also very appreciative of the significant contribution that Lars has made to the success of Tate & Lyle during his time with the business and we wish him well for the future."

 

There are no further disclosures to be made in connection with Mr Foots' appointment pursuant to paragraph 6.4.8 of the Financial Conduct Authority's Listing Rules.

 

 

For more information contact Tate & Lyle PLC:

 

Investors and analysts

Christopher Marsh, VP Investor Relations

Tel: Mobile: +44 (0) 7796 192 688

 

Media

Nick Hasell, FTI Consulting

Tel: Mobile: +44 (0) 7825 523 383

Tel: Office: +44 (0) 203 727 1340

Email: tate@fticonsulting.com

 

About Tate & Lyle PLC:

 

Supported by our 165-year history of ingredient innovation, we partner with customers to provide consumers with healthier and tastier choices when they eat and drink. We are proud that millions of people around the world consume products containing our ingredients and solutions every day. Through our leading expertise in sweetening, mouthfeel and fortification, we develop ingredients and solutions which reduce sugar, calories and fat, add fibre and protein, and provide texture and stability to food and drink in categories including beverages, dairy, bakery, snacks, soups, sauces, and dressings.

 

Tate & Lyle recently acquired CP Kelco, a leading provider of pectin, speciality gums and other nature-based ingredients to create a leader in mouthfeel, significantly enhancing our solutions capabilities. Following this combination, we now have more than 5,000 employees working in around 75 locations in 39 countries, serving customers in more than 120 countries. Science, Solutions, Society is our brand promise and how we will achieve our purpose of Transforming Lives through the Science of Food. By living our purpose, we believe we can successfully grow our business and have a positive impact on society. We live our purpose in three ways, by supporting healthy living, building thriving communities and caring for our planet.

 

Tate & Lyle is listed on the London Stock Exchange under the symbol TATE.L. American Depositary Receipts trade under TATYY. For the year ended 31 March 2024, and on a pro forma basis which assumes for illustrative purposes that the combination with CP Kelco took place on 1 April 2023, revenue for the enlarged Tate & Lyle Group would have been £2.25 billion. For more information, please visit www.tateandlyle.com or follow Tate & Lyle on LinkedInX (Twitter)Facebook or YouTube .

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOASEEFWMEISEID
Date   Source Headline
3rd Jun 20263:20 pmRNSForm 8.3 - Tate & Lyle plc
3rd Jun 20263:16 pmRNSForm 8.3 TATE & LYLE PLC
3rd Jun 20262:25 pmRNSForm 8.5 (EPT/NON-RI) - TATE & LYLE PLC
3rd Jun 20261:56 pmEQSForm 8.3 - The Vanguard Group, Inc.: Tate & Lyle plc
3rd Jun 20261:56 pmRNSForm 8.3 - Tate & Lyle plc
3rd Jun 20261:40 pmRNSForm 8.3 - Tate & Lyle plc
3rd Jun 202611:57 amRNSForm 8.5 (EPT/RI) - TATE & LYLE PLC
3rd Jun 202611:15 amRNSForm 8.5 (EPT/NON-RI)-Tate & Lyle plc
3rd Jun 202611:11 amRNSForm 8.5 (EPT/NON-RI)-Tate & Lyle plc
3rd Jun 202611:04 amRNSForm 8.5 (EPT/RI)-Tate & Lyle plc
3rd Jun 202611:02 amRNS20260602_TATE & LYLE_8.5 EPT RI_UK_MLI
3rd Jun 202610:41 amRNSForm 8.3 - Tate & Lyle PLC
3rd Jun 202610:24 amRNSForm 8.5 (EPT/RI)
2nd Jun 20265:13 pmRNSForm 8.5 (EPT/RI)-Tate & Lyle plc Amend
2nd Jun 20265:00 pmRNSForm 8.5 (EPT/NON-RI) - TATE & LYLE PLC
2nd Jun 20264:33 pmRNSForm 8.5 (EPT/RI) - TATE & LYLE PLC
2nd Jun 20263:20 pmRNSForm 8.3 - Tate & Lyle plc
2nd Jun 20263:00 pmRNSForm 8.3 TATE & LYLE PLC
2nd Jun 20262:47 pmRNSForm 8.5 (EPT/RI)-Amend Tate & Lyle PLC
2nd Jun 20262:30 pmRNSAnnual Financial Report and Notice of Meeting 2026
2nd Jun 202612:33 pmRNSForm 8.3 - Tate & Lyle PLC
2nd Jun 202611:47 amRNSForm 8.5 (EPT/NON-RI)-Tate & Lyle plc
2nd Jun 202611:45 amRNS20260601_TATE & LYLE_8.5 EPT RI_UK_MLI
2nd Jun 202611:44 amRNSForm 8.5 (EPT/NON-RI)-Tate & Lyle plc
2nd Jun 202611:32 amRNSForm 8.5 (EPT/RI)-Tate & Lyle plc
2nd Jun 202611:04 amRNSForm 8.5 (EPT/RI)-Amend Tate & Lyle PLC
2nd Jun 20268:42 amRNSForm 8.5 (EPT/RI)
1st Jun 20265:27 pmRNS20260526_TATE & LYLE_8.5 EPT RI_UK_MLI_replacement
1st Jun 20265:22 pmRNS20260526_TATELYLE8.5 EPT NON-RI BOFASE_replacement
1st Jun 20265:17 pmRNS20260522_TATE & LYLE_8.5 EPT RI_UK_MLI_replacement
1st Jun 20265:10 pmRNSForm 8.5 (EPT/RI)-Tate & Lyle plc Amend
1st Jun 20264:55 pmRNS20260521_TATE & LYLE_8.5 EPT RI_UK_MLI_replacement
1st Jun 20263:35 pmRNSDirector/PDMR Shareholding
1st Jun 20263:30 pmRNSForm 8.3 - Tate & Lyle plc
1st Jun 20263:20 pmRNSForm 8.3 TATE & LYLE PLC
1st Jun 20263:20 pmRNSForm 8.3 - Tate & Lyle plc
1st Jun 20262:26 pmPRNInvesco Ltd: Form 8.3 - Tate & Lyle PLC; Public dealing disclosure
1st Jun 20262:17 pmRNSForm 8.3 - Tate & Lyle plc
1st Jun 20262:12 pmRNSForm 8.3 - Tate & Lyle plc
1st Jun 202611:45 amRNSForm 8.5 (EPT/RI) - TATE & LYLE PLC
1st Jun 202611:37 amRNSForm 8.5 (EPT/NON-RI) - TATE & LYLE PLC
1st Jun 202611:24 amRNSForm 8.5 (EPT/NON-RI)-Tate & Lyle plc
1st Jun 202611:20 amRNSForm 8.5 (EPT/RI)-Tate & Lyle plc
1st Jun 202611:11 amBUSForm 8.3 - Tate & Lyle PLC
1st Jun 202611:00 amRNSTotal Voting Rights
1st Jun 202610:52 amRNSForm 8.3 – Tate & Lyle plc
1st Jun 202610:49 amRNS20260529_TATE & LYLE_8.5 EPT NON-RI_UK_BOFASE
1st Jun 202610:47 amRNS20260529_TATE & LYLE_8.5 EPT RI_UK_MLI
1st Jun 202610:29 amRNSForm 8.3 - Tate & Lyle PLC
1st Jun 20268:48 amRNSForm 8.5 (EPT/RI)

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.